New data integrating multitargeted antifolates into treatment of first-line and relapsed non-small-cell lung cancer

Clinical Lung Cancer

Volumn 9, Issue SUPPL. 3, 2008, Pages

  Scagliotti, Giorgio Vittorio ^a   Selvaggi, Giovanni ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

Carboplatin; Dihydrofolate reductase; Glycinamide ribonucleotide formyltransferase; Pemetrexed; Thymidylate synthase; Vitamin b12

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CISPLATIN; CYANOCOBALAMIN; DEXAMETHASONE; DIHYDROFOLATE REDUCTASE; DOCETAXEL; ERLOTINIB; FOLIC ACID; GEFITINIB; GEMCITABINE; GLYCOSYLTRANSFERASE INHIBITOR; GRANULOCYTE COLONY STIMULATING FACTOR; MULTIVITAMIN; OXALIPLATIN; PEMETREXED; PHOSPHORIBOSYLGLYCINAMIDE FORMYLTRANSFERASE; THYMIDYLATE SYNTHASE;

ALOPECIA; ANEMIA; CANCER CHEMOTHERAPY; CANCER RELAPSE; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DIARRHEA; DIET SUPPLEMENTATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG INDUCED DISEASE; DRUG RESPONSE; FATIGUE; FEBRILE NEUTROPENIA; GENE EXPRESSION; HUMAN; INFECTION; LIVER FUNCTION; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MULTIPLE CYCLE TREATMENT; NAUSEA; NAUSEA AND VOMITING; NEUTROPENIA; PHARMACOGENOMICS; PREMEDICATION; RANDOMIZED CONTROLLED TRIAL; RASH; RECOMMENDED DRUG DOSE; REVIEW; SENSORY NEUROPATHY; SIDE EFFECT; STOMATITIS; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT OUTCOME; VITAMIN SUPPLEMENTATION; VOMITING;

EID: 63849201527     PISSN: 15257304     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLC.2008.s.018     Document Type: Article

References (45)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2007. CA Cancer J Clin 2007; 57:43-66.
2. Kelly K, Crowley J, Bunn PA Jr, et al. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non--small-cell lung cancer: a Southwest Oncology Group trial. J Clin Oncol 2001; 19:3210-8.
3. Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002; 346:92-8.
4. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevaci- zumab for non-small-cell lung cancer. [published correction appears in N Engl J Med 2007; 356:318]. N Engl J Med 2006; 355:2542-50.
5. Manegold C, von Pawel J, Zatloukal P, et al. Randomised, double-blind mul- ticenter phase III study of bevacizumab in combination with cisplatin and gemcitabine in chemotherapy-naive patients with advanced or recurrent non-squa- mous non-small cell lung cancer (NSCLC): BO17704. J Clin Oncol 2007; 25(18 suppl):388s (Abstract LBA7514).
6. Goldman ID, Zhao R. Molecular, biochemical, and cellular pharmacology of pemetrexed. Semin Oncol 2002; 29(suppl 18):3-17.
7. Schultz RM, Patel VF, Worzalla JF, et al. Role of the thymidylate synthase in the antitumor activity of the multitargeted antifolate, LY231514. Anticancer Res 1999; 19:437-43.
8. Chen VJ, Bewley JR, Andis SL, et al. Preclinical cellular pharmacology of LY231514 (MTA): a comparison with methotrexate, LY309887 and raltitrexed for their effects on intracellular folate and nucleoside triphosphate pools in CCRF-CEM cells. Br J Cancer 1998; 78(suppl 3):27-34.
9. Hanauske AR, Eismann U, Oberschmidt O, et al. In vitro chemosensitivity of freshly explanted tumor cells to pemetrexed is correlated with target gene expression. Invest New Drugs 2007; 25:417-23.
10. Gomez HL, Santillana SL, Vallejos CS, et al. A phase II trial of pemetrexed in locally advanced breast cancer: clinical response and association with molecular target expression. Clin Cancer Res 2006; 12:832-8.
11. Giovannetti E, Mey V, Nannizzi S, et al. Cellular and pharmacogenetics foundation of synergistic interaction of pemetrexed and gemcitabine in human non-small-cell lung cancer cells. Mol Pharmacol 2005; 68:110-8.
12. Schmid M, Sen M, Rosenbach MD, et al. A methylthioadenosine phosphorylase (MTAP) fusion transcript identifies a new gene on chromosome 9p21 that is frequently deleted in cancer. Oncogene 2000; 19:5747-54.
13. Chattopadhyay S, Zhao R, Tsai E, et al. The effect of a novel transition state inhibitor of methylthioadenosine phosphorylase on pemetrexed activity. Mol Cancer Ther 2006; 5:2549-55.
14. Smit EF, Mattson K, von Pawel J, et al. ALIMTA (pemetrexed disodium) as second-line treatment of non-small-cell lung cancer: a phase II study. Ann Oncol 2003; 14:455-60.
15. Hanna N, Shepherd FA, Fossella FV, et al. Randomized phase III trial of peme- trexed versus docetaxel in patients with non-smallcell lung cancer previously treated with chemotherapy. J Clin Oncol 2004; 22:1589-97.
16. Clarke SJ, Abratt R, Goedhals L, et al. Phase II trial of pemetrexed disodium (AL- IMTA, LY231514) in chemotherapy-naïve patients with advanced non-small-cell lung cancer. Ann Oncol 2002; 13:737-41.
17. Rusthoven JJ, Eisenhauer E, Butts C, et al. Multitargeted antifolate LY231514 as first-line chemotherapy for patients with advanced non-small-cell lung cancer: a phase II study. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1999;17:1194-9.
18. Gridelli C, Kaukel E, Gregorc V, et al. Single-agent pemetrexed or sequential pemetrexed/gemcitabine as front-line treatment of advanced non-small cell lung cancer in elderly patients or patients ineligible for platinum-based chemotherapy: a multicenter, randomized, phase II trial. J Thorac Oncol 2007; 2:221-9.
19. Niyikiza C, Baker SD, Seitz DE, et al. Homocysteine and methylmalonic acid: markers to predict and avoid toxicity from pemetrexed therapy. Mol Cancer Ther 2002; 1:545-52.
20. Nakagawa K, Kudoh S, Matsui K, et al. A phase I study of pemetrexed (LY231514) supplemented with folate and vitamin B12 in Japanese patients with solid tumors. Br J Cancer 2006; 95:677-82.
21. Morrow PH, Glisson BS, Ginsberg LE, et al. A phase I dose escalation study of pemetrexed in patients with advanced head and neck squamous cell cancer (HNSCC). J Clin Oncol 2007; 25(18 suppl):312s (Abstract 6055).
22. Socinski MA, Raju RN, Richards DA, et al. The impact of shortened vitamin supplementation lead-in time before pemetrexed in patients with relapsed SCLC. J Thor Oncol 2007; 2(suppl 4):S829 (Abstract P1-229).
23. Eli Lilly and Company. Alimta® product information. Physicians' Desk Reference. Montvale, NJ: Thomson PDR, 2005:1824-8.
24. Manegold C, Gatzemeier U, von Pawel J, et al. Front-line treatment of advanced non-small-cell lung cancer with MTA (LY231514, pemetrexed disodium, Alimta) and cisplatin: a multicenter phase II trial. Ann Oncol 2000; 11:435-40.
25. Shepherd FA, Dancey J, Arnold A, et al. Phase II study of pemetrexed disodium, a multitargeted antifolate, and cisplatin as first-line therapy in patients with advanced non-small cell lung carcinoma: a study of the National Cancer Institute of Canada clinical trials group. Cancer 2001; 92:595-600.
26. Scagliotti GV, Kortsik C, Dark GG, et al. Pemetrexed combined with oxaliplatin or carboplatin as first-line treatment in advanced non-small cell lung cancer: a multicenter, randomized, phase II trial. Clin Cancer Res 2005; 11:690-6.
27. Zinner RG, Fossella FV, Gladish GW, et al. Phase II study of pemetrexed in combination with carboplatin in the first-line treatment of advanced non-small cell lung cancer. Cancer 2005; 104:2449-56.
28. Grønberg BH, Bremnes R, Aasebø U, et al. Pemetrexed + carboplatin versus gem- citabine + carboplatin in the treatment of stage IIIB/IV non-small cell lung cancer. J Clin Oncol 2007; 25(18 suppl):389s (Abstract 7517).
29. Lilly Files for European Approval of ALIMTA® (pemetrexed for injection) for First-Line Treatment of Non-Small Cell Lung Cancer [press release]. Indianapolis: Eli Lilly. Available at: http://newsroom.lilly.com/ ReleaseDetail. cfm?ReleaseID=264972. Accessed: March 14, 2007.
30. Barlési F, Jacot W, Astoul P, et al. Second-line treatment for advanced non-small cell lung cancer: a systematic review. Lung Cancer 2006; 51:159-72.
31. Shepherd FA, Dancey J, Ramlau R, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000; 18:2095-103.
32. Fossella FV, DeVore R, Kerr RN, et al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group [published correction appears in J Clin Oncol 2004; 22:209]. J Clin Oncol 2000;18:2354-62.
33. Shepherd FA, Rodrigues Pereira J, Ciuleanu TE, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005; 353:123-32.
34. U.S. Food and Drug Administration. Patient Information Sheet Gefitinib (marketed as Iressa). Rockville, MD: U.S. Department of Health and Human Services, 2005.
35. Cohen MH, Johnson JR, Wang YC, et al. FDA drug approval summary: peme- trexed for injection (Alimta) for the treatment of non-small cell lung cancer. Oncologist 2005; 10:363-8.
36. Pujol JL, Paul S, Chouaki N, et al. Survival without common toxicity criteria grade 3/4 toxicity for pemetrexed compared with docetaxel in previously treated patients with advanced non-small cell lung cancer (NSCLC): a risk-benefit analysis. J Thorac Oncol 2007; 2:397-401.
37. Pujol JL, Shaharyar S, Kortsik C, et al. Post study docetaxel in non-small cell lung cancer (NSCLC) patients after discontinuation from a randomized phase III trial of pemetrexed versus docetaxel: an exploratory analysis. Proc Am Soc Clin Oncol 2004; 22:650 (Abstract 7135).
38. Weiss GJ, Rosell R, Fossella F, et al. The impact of induction chemotherapy on the outcome of second-line therapy with pemetrexed or docetaxel in patients with advanced non-small-cell lung cancer. Ann Oncol 2007; 18:453-60.
39. Paez JG, Jänne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004; 304:1497-1500.
40. Ceppi P, Volante M, Saviozzi S, et al. Squamous cell carcinoma of the lung compared with other histotypes shows higher messenger RNA and protein levels for thymidylate synthase. Cancer 2006; 107:1589-96.
41. Peterson P, Park K, Fossella F, et al. Is pemetrexed more effective in patients with non-squamous histology? A retrospective analysis of a phase III trial of peme- trexed vs docetaxel in previously treated patients with advanced non-small cell lung cancer (NSCLC). Eur J Cancer 2007; 5(suppl 4):363 (Abstract 6521).
42. Kelly K, Chansky K, Gaspar LE, et al. Updated analysis of SWOG 0023: a randomized phase III trial of gefitinib versus placebo maintenance after definitive chemoradiation followed by docetaxel in patients with locally advanced stage III non-small cell lung cancer. J Clin Oncol 2007; 25(18 suppl):388s (Abstract 7513).
43. Fidias P, Dakhil S, Lyss A, et al. Phase III study of immediate versus delayed docetaxel after induction therapy with gemcitabine plus carboplatin in advanced non-small-cell lung cancer: updated report with survival. J Clin Oncol 2007; 25(18 suppl):388s (Abstract LBA7516).
44. Bischof M, Weber KJ, Blatter J, et al. Interaction of pemetrexed disodium (AL- IMTA, multitargeted antifolate) and irradiation in vitro. Int J Radiat Oncol Biol Phys 2002; 52:1381-8.
45. Seiwert TY, Connell PP, Mauer AM, et al. A phase I study of pemetrexed, carboplatin, and concurrent radiotherapy in patients with locally advanced or metastatic non-small cell lung or esophageal cancer. Clin Cancer Res 2007; 13:515-22.